Crizanlizumab to prevent crises in sickle cell disease

Abstract

Crizanlizumab (Adakveo) is a new monoclonal antibody therapy for the prevention of recurrent vaso‐occlusive crises in patients with sickle cell disease. This article discusses its mode of action, efficacy and place in therapy.